ZA913509B - Method for preventing,stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor - Google Patents

Method for preventing,stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor

Info

Publication number
ZA913509B
ZA913509B ZA913509A ZA913509A ZA913509B ZA 913509 B ZA913509 B ZA 913509B ZA 913509 A ZA913509 A ZA 913509A ZA 913509 A ZA913509 A ZA 913509A ZA 913509 B ZA913509 B ZA 913509B
Authority
ZA
South Africa
Prior art keywords
combination
stabilizing
ace inhibitor
cholesterol lowering
preventing
Prior art date
Application number
ZA913509A
Other languages
English (en)
Inventor
James L Bergey
L Bergey James
Werner Tshcollar
Tshcollar Werner
Cary S Yonce
S Yonce Cary
James C Kawano
C Kawano James
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of ZA913509B publication Critical patent/ZA913509B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA913509A 1990-05-15 1991-05-08 Method for preventing,stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor ZA913509B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52426690A 1990-05-15 1990-05-15

Publications (1)

Publication Number Publication Date
ZA913509B true ZA913509B (en) 1992-02-26

Family

ID=24088484

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA913509A ZA913509B (en) 1990-05-15 1991-05-08 Method for preventing,stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor

Country Status (15)

Country Link
EP (1) EP0457514B1 (xx)
JP (1) JPH04226921A (xx)
KR (1) KR100200467B1 (xx)
AT (1) ATE141514T1 (xx)
AU (1) AU651579B2 (xx)
CA (1) CA2040865C (xx)
DE (1) DE69121464T2 (xx)
DK (1) DK0457514T3 (xx)
ES (1) ES2090244T3 (xx)
GR (1) GR3021703T3 (xx)
HU (1) HU212102B (xx)
IE (1) IE77637B1 (xx)
NZ (1) NZ237929A (xx)
PT (1) PT97660B (xx)
ZA (1) ZA913509B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
WO1993013801A1 (en) * 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
AU1095695A (en) * 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
DE4402379C2 (de) * 1994-01-27 1997-09-25 Lohmann Therapie Syst Lts Orale Arzneiform mit sauren Wirkstoffen und Verfahren zu ihrer Herstellung
JP3883205B2 (ja) * 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
EP1514543A1 (en) 1997-08-29 2005-03-16 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
SI20305A (sl) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US6172441B1 (en) 1999-06-28 2001-01-09 Visteon Global Technologies, Inc. Rotor assembly
DE60022525T2 (de) 1999-08-30 2006-06-14 Sanofi Aventis Deutschland Ramipril zur vorbeugung von kardiovaskulären vorfällen
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2003092729A1 (de) * 2002-05-03 2003-11-13 Hexal Ag Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
WO2004085448A2 (en) * 2003-03-19 2004-10-07 Genzyme Corporation Unsaturated phosphinyl-phosphonate phosphate transport inhibitors
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
CN1903364B (zh) * 2005-07-26 2011-06-22 安徽省现代中药研究中心 含有血管紧张素转化酶抑制剂和苯氧酸类化合物的药物组合物
AU2009322999A1 (en) * 2008-12-01 2011-06-30 Invasc Therapeutics, Inc. Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit

Also Published As

Publication number Publication date
JPH04226921A (ja) 1992-08-17
DE69121464T2 (de) 1997-03-27
ATE141514T1 (de) 1996-09-15
PT97660A (pt) 1992-02-28
AU651579B2 (en) 1994-07-28
ES2090244T3 (es) 1996-10-16
IE911431A1 (en) 1991-11-20
GR3021703T3 (en) 1997-02-28
IE77637B1 (en) 1997-12-31
NZ237929A (en) 1997-06-24
EP0457514A1 (en) 1991-11-21
KR910019614A (ko) 1991-12-19
AU7627091A (en) 1991-11-21
CA2040865A1 (en) 1991-11-16
DE69121464D1 (de) 1996-09-26
PT97660B (pt) 1998-09-30
CA2040865C (en) 2002-07-23
HU212102B (en) 1996-02-28
EP0457514B1 (en) 1996-08-21
DK0457514T3 (da) 1996-09-16
HU911620D0 (en) 1991-11-28
KR100200467B1 (ko) 1999-06-15
HUT57993A (en) 1992-01-28

Similar Documents

Publication Publication Date Title
ZA913509B (en) Method for preventing,stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
GR3035526T3 (en) Retroviral protease inhibitors.
AU5074196A (en) Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
GR3026222T3 (en) Novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
IL102571A0 (en) Pharmaceutical composition for the treatment of heart failure containing an inhibitor of neutral endopeptidase
GR3002698T3 (en) Drug compositions stabilized against oxidation and discoloration
KR900009079A (ko) 비스(3,5-디-tert-부틸-4-히드록시페닐티오)메탄 함유 콜레스테롤 저하제겸 아테롬성 동맥 경화증 치료제
GR3026665T3 (en) Dual action inhibitors.
IL109802A0 (en) Pharmaceutical agents for treatment of emesis
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
DK0458287T3 (da) Anvendelse af magnesium-pyridoxal-5-phosphat-glutaminat til forebyggelse af sygdomme forårsaget af vaskulære læsioner
EP0631760A3 (en) Operating area with improved construction of the critical zone panel.
AU4228593A (en) Low level laser for soft tissue treatment
AU7854094A (en) Use of amiodarone for the treatment of heart failure
EP0381074A3 (en) Method for facilitating dieting employing an ace inhibitor
AU7719491A (en) Therapeutic compound
ZA971715B (en) Method of reducing tissue damage associated with ischemia
IL132504A0 (en) Methods for reducing fibrinogen
FR2708181B3 (fr) Elévateur de lit table élévatrice.
ZA93744B (en) Phosphonoxy and carbonate derivatives of taxol.
FR2714717B1 (fr) Procédé d'oxydation des imbrûlés de matières hydrocarbonées.
GB9309871D0 (en) Surgical operating tables
GB9309826D0 (en) Surgical operating tables